Home / Stocks / Balaxi Pharma Ltd
BALAXI

Balaxi Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹37.3

Change

+5.65 (17.85%)

Open

₹31.8

Prev. Close

₹31.65

Day High

₹37.98

Day Low

₹31.8

Volume Analysis

Traded

3,270,918

Delivered

1,016,627

Delivery %

31.08%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (4)

  • •Low return on equity (0.59%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (36/100)
  • •Low operating margin (4.3%)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹45.76 ₹41.87 ₹39.58 ₹35.69 ₹33.4 ₹29.51 ₹27.22
Fibonacci ₹41.87 ₹39.51 ₹38.05 ₹35.69 ₹33.33 ₹31.87 ₹29.51
Camarilla ₹39.0 ₹38.43 ₹37.87 ₹35.69 ₹36.73 ₹36.17 ₹35.6

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+31.85%

1 Week

+56.46%

1 Month

+76.78%

3 Months

+66.52%

6 Months

+48.84%

1 Year

+3.67%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

0.0%

Net margin 0.98% × asset turnover 0.0x × equity multiplier 1.0x

Company Overview

Sector

Healthcare

Market Cap

₹175 Cr

P/E (TTM)

51.8

ROE

0.59%

Book Value

₹46.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Balaxi Pharma Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 36/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (0.59%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

36/100 — Weak

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

4

Valuation

23

Cash Flow

0

Corporate Governance

43

Momentum

64

Institutional Ownership

31

Business Quality

27

Risk & Volatility

26

Liquidity

32

From Screener.in

  • +Stock is trading at 0.69 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of 3.15% over past five years.
  • −Company has a low return on equity of -3.58% over last 3 years.
  • −Company has high debtors of 184 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Q2/H1 FY27 investor presentation: revenue rose 39.4% to ₹80.5 crore in Q2; Jadcherla facility now operational.

Published unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.

Press Release 12 Nov

Q2 FY27 revenue rose 45% to ₹81.37 crore; EBITDA up 338%, PAT up 450%; Jadcherla facility operational.

Updates 12 Nov

Board approved Q2 FY26 results and noted WHO-GMP certification; Jadcherla plant now has 34 approved products.

Q2 FY26 results approved; Jadcherla plant received WHO-GMP certification, producing 22 products with 34 approved.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 55 61 60 66 77 73 76 71 56 73 71 81 81
Expenses + 44 47 46 56 67 69 64 67 55 69 71 76 76
Operating Profit 11 14 13 10 11 4 13 4 1 3 0 5 5
OPM % 19.66% 22.45% 22.51% 15.38% 13.69% 5.44% 16.45% 5.88% 2.06% 4.26% 0.17% 5.78% 6.3%
Other Income + 6 2 -1 -2 -4 4 -2 -2 2 0 3 -1 -1
Interest 0 0 1 0 0 1 1 1 1 1 1 1 1
Depreciation 1 0 1 0 0 0 0 0 0 1 1 1 1
Profit before tax 16 14 11 7 6 6 10 1 1 2 1 2 2
Tax % 7.92% 4.77% 4.87% 12.06% 17.41% 11.7% 10.56% 67.03% 84.06% 80.75% 56.43% 38.28% 43.07%
Net Profit + 14 14 11 6 5 5 9 0 0 0 1 1 1
EPS in Rs 3 3 2 1 1 1 2 0 0 0 0 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -37 -30 -26 -1 41 21 27 8 -27 -1 -7 14 45

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 0 0 0 0 14 46 231 279 336 241 293 270 305
Expenses + 0 0 0 1 12 37 189 229 279 197 254 261 292
Operating Profit 0 0 0 -1 2 8 43 51 57 45 38 10 13
OPM % 33.0% -120.0% — — 11.0% 18.0% 18.0% 18.0% 17.0% 18.0% 13.0% 3.5% 4.3%
Other Income + 0 0 0 0 1 1 2 5 3 -38 -4 3 1
Interest 0 0 0 0 0 0 0 1 1 3 4 5 4
Depreciation 0 0 0 0 0 0 0 1 2 2 2 2 3
Profit before tax 0 0 0 -1 2 9 44 55 57 2 29 5 7
Tax % 27.0% -36.0% 0.0% 0.0% 19.0% 31.0% 14.0% 13.0% 19.0% 219.0% 13.0% 73.0% —
Net Profit + 0 0 0 -1 2 6 38 48 46 -2 25 1 3
EPS in Rs 0 0 0 -1 1 1 8 10 9 0 5 0 1
Dividend Payout % 91.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth -14 -58 -100 — — 236 407 21 20 -28 21 -8 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 0 0 -1 -1 0 18 55 103 173 190 221 238 243
Borrowings + 0 0 0 0 0 0 4 4 13 19 53 58 52
Other Liabilities + 0 0 0 0 3 8 31 60 43 38 25 30 36
Total Liabilities 4 4 2 2 6 36 100 176 240 258 310 337 341
Fixed Assets + 0 0 0 0 0 0 2 29 41 41 41 82 82
CWIP 0 0 0 0 0 0 0 1 3 2 22 0 0
Investments 3 3 0 0 0 0 3 0 0 0 0 0 0
Other Assets + 0 0 2 2 6 36 94 147 195 215 247 255 259
Total Assets 4 4 2 2 6 36 100 176 240 258 310 337 341
Equity Capital 3 3 3 3 3 10 10 10 10 11 11 11 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 0 0 0 -1 -2 -14 0 34 6 5 -35 -4
Cash from Investing Activity + -3 0 3 0 0 0 -6 -28 -11 -1 -22 -21
Cash from Financing Activity + 2 0 0 0 0 18 4 0 26 30 34 0
Net Cash Flow -1 0 2 -1 -2 4 -2 6 21 34 -23 -25
Free Cash Flow 0 0 0 -1 -2 -14 -3 7 -9 4 -57 -25
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 700 50 100 88 -97 -161 6 78 32 26 -83 2

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 71.22% → 65.99%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 10.18% 15.91% 17.11% 17.5% 17.5% 17.96% 25.12% 30.49% 32.24% 31.45% 31.45% 31.45%
Promoters 71.22% 66.86% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99%
FII 18.57% 17.21% 16.88% 16.48% 16.48% 16.02% 8.87% 3.5% 1.74% 0.0% 0.0% 0.0%
DII 0.03% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 2.56% 2.56% 2.56%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Balaxi Pharma Ltd (this stock) 175 51.8 0.69 0.59%
Makers Laboratories Ltd. 169 22.6 2.15 3.17%
Take Limited 192 22.0 5.6 16.5%
Nectar Lifesciences Ltd. 193 — 0.34 -31.3%
Bilcare Ltd. 202 5.55 1.13 1.39%
Brooks Lab Limited 203 58.7 1.08 22.0%
Natural Capsules Limited 144 — 0.66 -9.45%

Which Mutual Funds Hold Balaxi Pharma Ltd?

Frequently Asked Questions about Balaxi Pharma Ltd

Community Sentiment

What are other investors saying about Balaxi Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.